As immunology experts, we work with clients to discover new targets and develop treatments for cancer, autoimmune diseases such as multiple sclerosis, and also those working in regenerative medicine.
Please get in touch for further information on our service offerings and possibilities.
A hallmark of cancer is its characteristic immunosuppressive immune environment.
We can design specialised assays and programs of work to understand immune function in the tumour microenvironment and how this might be manipulated therapeutically by either antibodies or small molecules. Assays are validated with benchmark antibodies and include:
At Aquila, we have world-leading expertise in research into multiple sclerosis (MS), a disease that requires understanding of immunology, inflammation and neuroscience.
We offer a suite of in vitro assays for clients seeking to reduce disease progression in MS by improving remyelination efficiency. These include an Oligodendrocyte Precursor Cell (OPC) culture assay to assess the effects of a test substance on proliferation and cell death.
Following compound screening in our OPC assay, your lead compound can be progressed to our Central Nervous System (CNS) slice model to assess remyelination efficiency following toxin-induced demyelination. This model is a powerful screening tool for potential regenerative therapies and gives biological results in line with larger and more time-consuming in vivo studies.
At Aquila, we offer CRO services to biotech and pharmaceutical companies developing treatments for a range of autoimmune diseases.
We can tailor immunology screening programs to discover the mechanisms of action (MOA) of your drug candidate for treating autoimmune disease. Such programs often involve a phenotypic screen in which specific cell types (e.g. T cells) are studied in the presence of the test compound(s).
Beyond the in vitro level, the academic expertise available to Aquila allows us to develop novel, biologically-relevant models of autoimmune disease, as well as potentially offering off-the-shelf models for routine screening.